Hookipa pharma CEO Peters sells $20,683 in shares
- Investing.com
Strategic Pivot | HOOKIPA's 80% workforce reduction and pausing of lead program signal a major shift towards focusing on high-potential areas like the HB-700 KRAS vaccine |
Pipeline Prospects | Explore HOOKIPA's ongoing collaborations with Gilead Sciences in HIV and HBV vaccines, offering potential milestone payments and royalties |
Financial Challenges | Delve into HOOKIPA's financial position, with cash reserves and partnerships offsetting concerns about long-term stability and weak profit margins |
Market Outlook | Analyst price targets range from $5 to $48, reflecting mixed sentiments on HOOKIPA's future amid restructuring and pipeline developments |
Metrics to compare | HOOK | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipHOOKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.6x | −0.2x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 0.0x | 2.7x | 2.6x | |
Price / LTM Sales | 0.0x | 17.3x | 2.8x | |
Upside (Analyst Target) | - | 132.5% | 65.0% | |
Fair Value Upside | Unlock | 20.0% | 9.6% | Unlock |